Gyre TherapeuticsGYRE
13F holders, Q3 2024 (September 30)37holders +7
10new positions
4sold out
$12.54avg. 13F price*
At the end of Q3 2024, 37 institutions reported holding Gyre Therapeutics Inc. (GYRE) in their 13F filings, up 7 from Q2 2024. 10 opened new positions and 4 sold out. The largest holders were BlackRock, Inc. ($6.5M), Vanguard Group Inc. ($4.3M) and Geode Capital Management, LLC ($3.8M).
- Company
- Gyre Therapeutics Inc.
- CUSIP
- 403783103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $698K |
| Exits | 4 | $514K |
All 13F filers, Q2 2024 → Q3 2024: 394,255 shares bought and 56,685 shares sold, net +337,570 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 37 holders
| BlackRock, Inc. | 0.00% | — | 514,421 | $6.5M |
| Vanguard Group Inc. | 0.00% | Add +46.9% | 340,171 | $4.3M |
| Geode Capital Management, LLC | 0.00% | Add +16.9% | 303,647 | $3.8M |
| Charles Schwab Investment Management Inc. | 0.00% | Add +392.2% | 113,648 | $1.4M |
| State Street Corp. | 0.00% | Add +8.8% | 104,490 | $1.3M |
| Northern Trust Corp. | 0.00% | Add +189.8% | 94,758 | $1.2M |
| Advantage Alpha Capital Partners LP | 0.08% | New | 26,634 | $334K |
| Goldman Sachs Group Inc. | 0.00% | New | 18,799 | $236K |
| Morgan Stanley | 0.00% | Add +150.5% | 18,222 | $229K |
| Bank of New York Mellon Corp | 0.00% | Reduce -31.5% | 12,507 | $157K |
| Rhumbline Advisers | 0.00% | Add +1.3% | 10,424 | $131K |
| Barclays PLC | 0.00% | Add +281.8% | 9,288 | $116K |
| Citigroup Inc. | 0.00% | Add +225.0% | 5,076 | $64K |
| Bank of America Corp. | 0.00% | Reduce -0.6% | 4,941 | $62K |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.00% | New | 3,861 | $48K |
| FMR LLC | 0.00% | New | 3,742 | $47K |
| Corebridge Financial, Inc. | 0.00% | Reduce -0.6% | 3,730 | $47K |
| UBS Group AG | 0.00% | Add +71.6% | 3,643 | $46K |
| Wells Fargo & Company | 0.00% | Add +3.9% | 3,103 | $39K |
| JPMorgan Chase & Co. | 0.00% | Add +1.9% | 3,032 | $38K |
| New York State Common Retirement Fund | 0.00% | Reduce -73.5% | 2,700 | $34K |
| Belvedere Trading LLC | 0.00% | New | 2,515 | $32K |
| BNP Paribas Financial Markets | 0.00% | Add +274.4% | 1,947 | $24K |
| Royal Bank of Canada | 0.00% | Reduce -8.4% | 964 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +244.6% | 858 | $11K |
| Ameritas Investment Partners, Inc. | 0.00% | No change | 683 | $9K |
| Legal & General Group Plc | 0.00% | No change | 603 | $8K |
| Activest Wealth Management | 0.00% | No change | 533 | $7K |
| California State Teachers Retirement System | 0.00% | No change | 505 | $6K |
| Osaic Holdings, Inc. | 0.00% | Reduce -31.2% | 441 | $6K |
| Amalgamated Bank | 0.00% | No change | 241 | $3K |
| Nisa Investment Advisors, LLC | 0.00% | New | 84 | $1K |
| Sterling Capital Management LLC | 0.00% | — | 21 | $263 |
| Earned Wealth Advisors, LLC | 0.00% | New | 6 | $75 |
| Danske Bank A/S | 0.00% | New | 1 | $13 |
| Cwm, LLC | 0.00% | New | 30 | $0 |
| Covestor Ltd | 0.00% | New | 6 | $0 |
"% of holder's portfolio" is GYRE's weight in each manager's 13F, not the share of Gyre Therapeutics Inc. the manager owns.